Anlotinib - CAS 1058156-90-3
Catalog number: B0084-474328
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Anlotibib is a multi-targetes kinase inhibitor of receptor tyrosine and could effectively resist the formation of new angiogenesis. It is undergoing a phase III clinical trial for therapy of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS).
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-474328 50 mg $228 In stock
B0084-474328 100 mg $398 In stock
Bulk Inquiry
Related CAS:
1360460-82-7 (hydrochloride)
Solid Powder
Soluble to 44 mg/mL DMSO.
Store at -20°C
Shelf Life:
2 years
Canonical SMILES:
1.Influences of Anlotinib on Cytochrome P450 Enzymes in Rats Using a Cocktail Method.
Sun W;Wang Z;Chen R;Huang C;Sun R;Hu X;Li W;Chen R Biomed Res Int. 2017;2017:3619723. doi: 10.1155/2017/3619723. Epub 2017 Dec 26.
The present study aimed to investigate the effect of anlotinib (AL3818) on pharmacokinetics of cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C6, CYP2D1, CYP2D2, and CYP3A1/2) by using five cocktail probe drugs in vivo. After pretreatment for 7 days with anlotinib (treatment group) or saline (control group) by oral administration, probe drugs phenacetin, tolbutamide, omeprazole, metoprolol, and midazolam were administered to rats by oral administration. Blood samples were obtained at a series of time-points and the concentrations of five probe drugs in plasma were determined by a UHPLC-MS/MS method. The results showed that treatment with anlotinib had no significant effect on rat CYP1A2, CYP2D2, and CYP2C6. However, anlotinib had a significant inductive effect on CYP2D1 and CYP3A1/2. Therefore, caution is needed during the concomitant use of anlotinib with other drugs metabolized by CYP2D1 and CYP3A1/2 because of potential drug-anlotinib interactions.
2.Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
Zhao J;Zhao H;Chi Y Neuroendocrinology. 2018;106(4):318-323. doi: 10.1159/000480402. Epub 2017 Aug 17.
PURPOSE: ;Both capecitabine alone and capecitabine in combination with temozolomide have activities against neuroendocrine tumors (NETs). However, the role of S-1 in NETs is still unknown. We performed a study to evaluate the safety and efficacy of the S-1/temozolomide (STEM) regimen in patients with locally advanced or metastatic NETs.;METHODS: ;A retrospective review was conducted in 20 patients with locally advanced or metastatic NETs treated with the STEM regimen. Of the patients, 15 (75.00%) had failed 1 or more lines of treatment with somatostatin analogues, sunitinib, everolimus, anlotinib, or other chemotherapy regimens. The patients received S-1 at 40 mg/m2 orally twice daily on days 1-14 and temozolomide 200 mg orally once daily on days 10-14 of a 21-day cycle. The patients were followed up for evidence of object response, toxicity, and progression-free survival.;RESULTS: ;Response to treatment was assessed using RECIST 1.1. Eight patients (40.00%) achieved a partial response (PR), and another 8 (40.00%) had stable disease (SD). The clinical benefit rate (PR and SD) was 80.00%. The median progression-free survival was not achieved. Only 1 patient (5.00%) had grade 3 adverse events.
3.Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft Tissue Sarcoma.
Chi Y;Fang Z;Hong XN;Yao Y;Sun P;Wang G;Du F;Sun Y;Wu Q;Qu G;Wang S;Song J;Yu J;Lu Y;Zhu X;Niu X;He Z;Wang J;Yu H;Cai J Clin Cancer Res. 2018 Jun 12. pii: clincanres.3766.2017. doi: 10.1158/1078-0432.CCR-17-3766. [Epub ahead of print]
PURPOSE: ;The prognosis for patients with refractory soft-tissue sarcoma (STS) is dismal. Anlotinib has previously shown antitumor activity on STS in preclinical and phase I studies.;EXPERIMENTAL DESIGN: ;Patients 18 years and older, progressing after anthracycline-based chemotherapy, naïve from angiogenesis inhibitors, with at least one measurable lesion according to RECIST 1.1, were enrolled. The main subtypes eligible were: undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), leiomyosarcoma (LMS), synovial sarcoma (SS), fibrosarcoma (FS), alveolar soft part sarcoma (ASPS) and clear cell sarcoma (CCS). Participants were treated with anlotinib. The primary endpoint was progression-free rate at 12 weeks (PFR 12 weeks).;RESULTS: ;166 patients were included in the final analysis. Overall, the PFR 12 weeks was 68% and objective response rate was 13% (95% CI 7.6%-18%). The median progression free survival (PFS) and overall survival (OS) were 5.6 and 12 months respectively. The PFR 12 weeks, median PFS and OS were: 58%, 4.1 and 11 months for UPS (n=19); 63%, 5.6 and 13 months for LPS (n=13); 75%, 11 and 15 months for LMS (n=26); 75%, 7.7 and 12 months for SS (n=47); 81%, 5.6 and 12 months for FS (n=18); 77%, 21 and not reached for ASPS (n=13); 54%, 11 and 16 months for CCS (n=7); 44%, 2.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products

CAS 356068-94-5 Toceranib

(CAS: 356068-94-5)

Toceranib (CAS 356068-94-5) is a potent ATP-competitive PDGFR and VEGFR inhibitor (Ki = 5 and 6 nM, respectively); inhibits phosphorylation of c-Kit and suppres...

CAS 446-72-0 Genistein

(CAS: 446-72-0)

Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by ...

(CAS: 1952236-05-3)

MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the...

CAS 300842-64-2 NVP-ACC789

(CAS: 300842-64-2)

NVP-ACC789 is a potent, selective and orally active inhibitor of the VEGF receptor tyrosine kinases, antagonizing tumor-driven angiogenesis

CAS 524722-52-9 Vandetanib hydrochloride

Vandetanib hydrochloride
(CAS: 524722-52-9)

Vandetanib hydrochloride is an anti-cancer drug that is used for the treatment of certain tumours of thethyroid gland. It acts as a kinase inhibitor of a number...

CAS 883986-34-3 AZD2932

(CAS: 883986-34-3)

AZD2932 is a new quinazoline ether inhibitor and is a high affinity inhibitor of VEFGR-2 and PDGFR. It has a balanced ~1:1 ratio of activity vs both VEGFR-2 an...

(CAS: 1903008-80-9)

Lazertinib, also known as YH-25448 and GNS-1480, is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible 3rd gene...

(CAS: 1246089-27-9)

This active molecular is an irreversible EGFR ( epidermal growth factor receptor ) tyrosine kinase inhibitor. Transtinib shows good anti-proliferative activity ...

CAS 656247-17-5 Nintedanib

(CAS: 656247-17-5)

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59...

Naquotinib mesylate
(CAS: 1448237-05-5)

Naquotinib is irreversible, third-generation, epidermal growth factor receptor (EGFR) inhibitor with IC50 value of 70 nM for NCI-H1650 cell growth. It can coval...

CAS 125697-92-9 Lavendustin A

Lavendustin A
(CAS: 125697-92-9)

Lavendustin A is an epidermal growth factor receptor inhibitor tyrosine kinase with IC50 value of 11 nM.

CAS 212142-18-2 Vatalanib succinate

Vatalanib succinate
(CAS: 212142-18-2)

Vatalanib succinate is a potent and orally bioactive VEGFR inhibitor (IC50 =37 and 77 nM for VEGFR-2 and -1, respectively) exhibiting potential antineoplastic a...

CAS 1308672-74-3 Sulfatinib

(CAS: 1308672-74-3)

Sulfatinib, an oral drug candidate, is a small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth...

CAS 184475-35-2 Gefitinib

(CAS: 184475-35-2)

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell ...

CAS 848133-17-5 HKI 357

HKI 357
(CAS: 848133-17-5)

HKI 357 is a potent and irreversible dual inhibitor of ErbB2 (HER2) and EGFR (IC50 = 33 and 34 nM, respectively). It inhibits EGFR autophosphorylation and proli...

CAS 388082-77-7 Lapatinib Ditosylate

Lapatinib Ditosylate
(CAS: 388082-77-7)

Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth ...

CAS 873837-23-1 BMS-599626 Hydrochloride

BMS-599626 Hydrochloride
(CAS: 873837-23-1)

BMS-599626 Hydrochloride is a selective and efficacious orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases with potential antineoplastic ...

CAS 894783-71-2 BIBF 1202

BIBF 1202
(CAS: 894783-71-2)

BIBF 1202 is the major in-vivo metabolite of BIBF 1120, which is an oral triple angiokinase inhibitor targeting VEGFR, PDGFR, FGFR. It is a related compound of ...

CAS 867331-64-4 TG 100572 Hydrochloride

TG 100572 Hydrochloride
(CAS: 867331-64-4)

TG 100572 is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases for VEGFR1/VEGFR2/FGFR1/Src/Fy...

CAS 1050500-29-2 AST-1306

(CAS: 1050500-29-2)

AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-ove...

Quick Inquiry

Verification code

Featured Items